BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21435890)

  • 1. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK
    Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
    Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Dewang PM; Kim DK
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4228-32. PubMed ID: 20621731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Jung SH; Lee HS; Dewang PM
    Eur J Med Chem; 2009 Feb; 44(2):568-76. PubMed ID: 18467006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of 5-(pyridin-2-yl)thiazoles as transforming growth factor-beta type1 receptor kinase inhibitors.
    Kim DK; Choi JH; An YJ; Lee HS
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2122-7. PubMed ID: 18262787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK
    Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 2-benzylamino-4(5)-(6-methylpyridin-2-yl)-5(4)-([1,2,4]triazolo[1,5-a]-pyridin-6-yl)thiazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Krishnaiah M; Jin CH; Sreenu D; Subrahmanyam VB; Rao KS; Son DH; Park HJ; Kim SW; Sheen YY; Kim DK
    Eur J Med Chem; 2012 Nov; 57():74-84. PubMed ID: 23047226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Jang Y; Lee HS; Park HJ; Yoo J
    J Med Chem; 2007 Jun; 50(13):3143-7. PubMed ID: 17552507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5).
    Li X; Wang L; Long L; Xiao J; Hu Y; Li S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 1-(6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-1,2,3-triazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Li F; Park Y; Hah JM; Ryu JS
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1083-6. PubMed ID: 23294702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
    Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5).
    Guo C; Zhang C; Li X; Li W; Xu Z; Bao L; Ding Y; Wang L; Li S
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5850-4. PubMed ID: 24055046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
    Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
    J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
    Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
    Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles.
    Řezníčková E; Tenora L; Pospíšilová P; Galeta J; Jorda R; Berka K; Majer P; Potáček M; Kryštof V
    Eur J Med Chem; 2017 Feb; 127():632-642. PubMed ID: 28135685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
    Sawyer JS; Beight DW; Britt KS; Anderson BD; Campbell RM; Goodson T; Herron DK; Li HY; McMillen WT; Mort N; Parsons S; Smith EC; Wagner JR; Yan L; Zhang F; Yingling JM
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3581-4. PubMed ID: 15177479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
    Li HY; Wang Y; Heap CR; King CH; Mundla SR; Voss M; Clawson DK; Yan L; Campbell RM; Anderson BD; Wagner JR; Britt K; Lu KX; McMillen WT; Yingling JM
    J Med Chem; 2006 Mar; 49(6):2138-42. PubMed ID: 16539403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor beta 1 type 1 receptor.
    Kim DK; Kim J; Park HJ
    Bioorg Med Chem Lett; 2004 May; 14(10):2401-5. PubMed ID: 15109621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.